MOTS-c
| Category | Other Peptides |
| Goals | Longevity & Anti-Aging |
| Evidence level | Preclinical (mostly rodent + cell; very limited human data) |
| Legal status | Research-only — not approved for human use |
| FDA status | Not FDA-approved; on PCAC 503A agenda Jul 23, 2026 (use evaluated: obesity & osteoporosis) |
| Half-life | Short; human PK not well characterized |
| Routes | Subcutaneous · Intramuscular |
| CAS / MW / Sequence | 1627580-64-6 · ~2174.6 g/mol · MRWQEMGYIFYPRKLR (16 aa) |
| Last reviewed | 2026-06-07 |
In one line
A mitochondrial-derived peptide (encoded in mtDNA) studied mainly in animals for metabolism, insulin sensitivity, and exercise-mimetic effects via AMPK activation.
Evidence at a glance
MOTS-c is a genuinely interesting endogenous peptide, but human therapeutic data are very limited. Most claims (fat loss, longevity, “exercise in a vial”) come from rodent and cell studies. Treat human-performance claims with caution. See Evidence Grading Explained and the Disclaimer.
Key Takeaways
- One of a handful of mitochondrial-derived peptides (MDPs) — encoded within the mitochondrial 12S rRNA gene, not the nuclear genome.
- Acts largely through AMPK, the cell’s master metabolic sensor, producing exercise-mimetic metabolic effects in animals.
- Reported preclinical effects: improved insulin sensitivity, glucose uptake, fatty-acid oxidation, and stress resistance.
- Not FDA-approved; sold as a research chemical. Prohibited in tested sport (gene/metabolic modulator class — flagged by anti-doping bodies).
- Popular in Longevity & Anti-Aging and metabolic-optimization communities, but human evidence is thin.
What Is It
MOTS-c (“Mitochondrial ORF of the 12S rRNA type-c”) is a 16-amino-acid peptide (sequence MRWQEMGYIFYPRKLR) encoded by a small open reading frame within the mitochondrial 12S rRNA gene. It is an endogenous signaling peptide — your cells make it — that circulates in blood and acts on metabolic tissues. Under metabolic stress it can translocate to the nucleus and influence stress-response gene expression. It is studied as a regulator of metabolic homeostasis and as a candidate longevity/metabolic agent.
Mechanism of Action
Mechanisms are supported mostly by cell and rodent studies:
- AMPK activation (cell/animal) — the central mechanism; drives glucose uptake, fatty-acid oxidation, and mitochondrial biogenesis while suppressing energy-consuming pathways.
- Nuclear translocation / stress-response genes (in vitro) — under metabolic stress MOTS-c moves to the nucleus and modulates antioxidant-response (ARE) gene expression.
- Exercise-mimetic metabolic reprogramming (animal) — improves insulin sensitivity and metabolic flexibility in rodents, resembling some effects of exercise.
- Direct protein interactions (emerging in vitro) — reported binding to targets such as CK2; mechanistic detail is still being worked out.
Limitations
Most mechanistic data are preclinical. How well exogenous (injected) MOTS-c reproduces the effects of endogenously produced peptide in humans is not well established.
Evidence by Outcome
| Outcome | Evidence | Notes |
|---|---|---|
| Insulin sensitivity / glucose metabolism | Preclinical | Strong rodent and cell data; minimal human |
| Fat oxidation / body composition | Preclinical | Animal models; human claims are extrapolation |
| Exercise capacity / “exercise mimetic” | Preclinical | Rodent studies; no controlled human performance trials |
| Healthspan / age-related decline | Preclinical | Animal/aging-biomarker data |
| Human performance / fat loss in users | Anecdotal | Widely reported; uncontrolled |
Reported Dosing
Not medical advice
Protocols as reported in community sources. There is no established human therapeutic dose. See Reconstitution & Dosing Math and Injection Technique.
| Route | Dose (reported) | Frequency | Cycle |
|---|---|---|---|
| Subcutaneous | ~5–10 mg/week (often split) | 2–3×/week | ~4–8 weeks |
| Intramuscular | Similar weekly totals | 2–3×/week | ~4–8 weeks |
Pharmacokinetics
As a 16-mer peptide, MOTS-c is expected to have a short circulating half-life and to be degraded by peptidases; reported community dosing is intermittent rather than daily. Detailed human PK is not well characterized. See Half-Life & Pharmacokinetics.
Side Effects & Risks
- Human safety data are limited. Reported tolerability is mostly anecdotal.
- Anecdotal: injection-site reactions, fatigue or flushing, transient changes in blood glucose — not systematically documented.
- Metabolic caution: because it affects glucose handling, theoretical interaction with diabetes medications / hypoglycemia risk is plausible but unstudied.
- Anti-doping: treated as a prohibited metabolic modulator in tested sport.
- Sourcing risk: research-chemical identity/purity vary — see Sourcing and Red Flags & Scams.
- See Side Effects & Risk Management.
Cycling
Anecdotal protocols run 4–8 week blocks with breaks. No evidence-based cycling standard exists. See Cycling.
Stacks It Appears In
- Metabolic / body-composition stacks alongside other GLP-1 or fat-loss agents (community use; no clinical validation).
- Longevity stacks discussed with NAD+ and other Longevity & Anti-Aging agents.
Comparisons
- vs SS-31 — both are “mitochondrial” peptides, but SS-31 is a cardiolipin-targeting tetrapeptide in clinical development, whereas MOTS-c is an endogenous AMPK-activating metabolic signal.
Sourcing & Quality
Sold as a lyophilized research chemical; identity and purity are not guaranteed. Evaluate before trusting any product: How to Read a CoA, Sourcing, Red Flags & Scams. Reconstitution and storage: Reconstitution & Dosing Math, Storage & Handling. No vendors are endorsed here.
Legal & Regulatory Status
(As of 2026-06-07.) Not FDA-approved for any use; sold as a research chemical. MOTs-C-related bulk drug substances (MOTs-C free base / acetate) are on the agenda of the FDA’s Pharmacy Compounding Advisory Committee (PCAC) meeting on July 23, 2026, being considered for inclusion on the 503A Bulks List; the uses FDA evaluated are obesity and osteoporosis (public docket FDA-2025-N-6895). Inclusion would only determine eligibility for traditional (503A) pharmacy compounding — it is not drug approval. Considered a prohibited substance in tested sport (metabolic/gene-expression modulator class). Status varies by country. See Regulatory & Legal Status.
FAQ
Is MOTS-c FDA-approved? No. It is not approved for human use.
Is it really “exercise in a syringe”? That framing comes from rodent studies showing exercise-like metabolic effects. There are no controlled human trials demonstrating equivalent benefit.
Is it banned in sport? Yes — it is treated as a prohibited metabolic modulator by anti-doping authorities.
How is it different from SS-31? SS-31 structurally protects the mitochondrial membrane (cardiolipin); MOTS-c is a metabolic signaling peptide acting through AMPK.
References
- Lee C. et al. (2015). “The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.” Cell Metabolism.
- “MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation.” Frontiers in Endocrinology (2023). Frontiers
- “MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases.” PubMed (2022). PubMed 36233287
- USADA. “What is the MOTS-c peptide?” (anti-doping status overview).
- U.S. FDA (2026). “July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee” — MOTs-C (free base/acetate), uses evaluated: obesity & osteoporosis; Docket FDA-2025-N-6895. fda.gov
← Other Peptides · Home Educational information only — not medical advice. See Disclaimer.